在头部和部状细胞癌中DSG-2,CXADR,CD46的表达和预后

Inga Marte Charlott Seuthe1, Lea Krause1, Markus Ruwe2

  • 1Department of Otorhinolaryngology, Head and Neck Surgery, University of Witten/Herdecke, Catholic Hospital Hagen, Dreieckstraße 15, Hagen 58097, Germany.

PubMed
概括

腺病毒受体DSG-2,CXADR和CD46在头部和部状细胞癌 (HNSCC) 中表达,但不会影响患者的存活率. 然而,它们在晚期瘤中的表达表明了基于腺病毒载体的瘤治疗的潜力.